Katarina Le Blanc

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. ncbi [Mesenchymal stem cells. Basic science and future clinical use]
    Katarina Le Blanc
    Hematologiska kliniken, Huddinge Universitetssjukhus
    Lakartidningen 99:1318-21, 1324. 2002
  2. ncbi Generation of immunosuppressive mesenchymal stem cells in allogeneic human serum
    Katarina Le Blanc
    Division of Clinical Immunology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Transplantation 84:1055-9. 2007
  3. ncbi HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells
    Katarina Le Blanc
    Division of Clinical Immunology, Centre for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Exp Hematol 31:890-6. 2003
  4. ncbi Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses
    Helen Karlsson
    Molecular Immunology Unit, Institute of Child Health, London, United Kingdom
    Blood 112:532-41. 2008
  5. doi Multipotent mesenchymal stromal cells and the innate immune system
    Katarina Le Blanc
    Department of Medicine, Karolinska Institutet, Haematology Centre, Karolinska University Hospital, Stockholm, Sweden
    Nat Rev Immunol 12:383-96. 2012
  6. pmc Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005
    Alan Tyndall
    Rheumatology, University Hospital Basel, Felix Platter Spital, Burgfelderstrasse 101, Basel, CH 4012, Switzerland
    Arthritis Res Ther 9:301. 2007
  7. pmc Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies
    Katarina Le Blanc
    Division of Clinical Immunology and Transfusion Medicine, Karolinska Institutet, Stockholm, Sweden
    Biol Blood Marrow Transplant 15:1108-15. 2009
  8. doi Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study
    Katarina Le Blanc
    Haematology Centre and Centre of Allogeneic Stem Cell Transplantation, Division of Clinical Immunology, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Lancet 371:1579-86. 2008
  9. ncbi Mesenchymal stem cells: properties and role in clinical bone marrow transplantation
    Katarina Le Blanc
    Division of Clinical Immunology, Karolinska Institutet, Karolinska University Hospital Huddinge, F79, SE 141 86 Stockholm, Sweden
    Curr Opin Immunol 18:586-91. 2006
  10. ncbi Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells
    K Le Blanc
    Hematology Center, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Leukemia 21:1733-8. 2007

Detail Information

Publications55

  1. ncbi [Mesenchymal stem cells. Basic science and future clinical use]
    Katarina Le Blanc
    Hematologiska kliniken, Huddinge Universitetssjukhus
    Lakartidningen 99:1318-21, 1324. 2002
    ....
  2. ncbi Generation of immunosuppressive mesenchymal stem cells in allogeneic human serum
    Katarina Le Blanc
    Division of Clinical Immunology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Transplantation 84:1055-9. 2007
    ..MSC generated in AB-serum suppressed lymphocyte proliferation in mixed lymphocyte cultures and after stimulation with phytohemagglutinin. MSC expanded in AB-serum and FCS have similar in vitro properties...
  3. ncbi HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells
    Katarina Le Blanc
    Division of Clinical Immunology, Centre for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Exp Hematol 31:890-6. 2003
    ..Mesenchymal stem cells (MSC) do not elicit alloreactive lymphocyte responses due to immune modulations. We investigated the immunologic properties of MSC after differentiation along three lineages: bone, cartilage, and adipose...
  4. ncbi Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses
    Helen Karlsson
    Molecular Immunology Unit, Institute of Child Health, London, United Kingdom
    Blood 112:532-41. 2008
    ..These data have major implications for immunotherapy of GVHD with MSCs and suggest that the effector functions of virus-specific T cells may be retained after MSC infusion...
  5. doi Multipotent mesenchymal stromal cells and the innate immune system
    Katarina Le Blanc
    Department of Medicine, Karolinska Institutet, Haematology Centre, Karolinska University Hospital, Stockholm, Sweden
    Nat Rev Immunol 12:383-96. 2012
    ..It is therefore important to study the crosstalk between MSCs and innate immunity, which ranges from the bone marrow niche to injured tissue...
  6. pmc Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005
    Alan Tyndall
    Rheumatology, University Hospital Basel, Felix Platter Spital, Burgfelderstrasse 101, Basel, CH 4012, Switzerland
    Arthritis Res Ther 9:301. 2007
    ..This review summarizes the findings of a 1-day meeting devoted to the subject with the aim of coordinating efforts...
  7. pmc Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies
    Katarina Le Blanc
    Division of Clinical Immunology and Transfusion Medicine, Karolinska Institutet, Stockholm, Sweden
    Biol Blood Marrow Transplant 15:1108-15. 2009
    ..81, P=.02) and aGVHD (HR 0.84, P=.05). These results indicate that LC30 is an independent prognostic factor for transplant outcome in matched unrelated SCT for myelogenous malignancies...
  8. doi Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study
    Katarina Le Blanc
    Haematology Centre and Centre of Allogeneic Stem Cell Transplantation, Division of Clinical Immunology, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Lancet 371:1579-86. 2008
    ..Mesenchymal stem cells modulate immune responses in vitro and in vivo. We aimed to assess whether mesenchymal stem cells could ameliorate GVHD after haemopoietic-stem-cell transplantation...
  9. ncbi Mesenchymal stem cells: properties and role in clinical bone marrow transplantation
    Katarina Le Blanc
    Division of Clinical Immunology, Karolinska Institutet, Karolinska University Hospital Huddinge, F79, SE 141 86 Stockholm, Sweden
    Curr Opin Immunol 18:586-91. 2006
    ..Therefore, in the future, MSCs might have implications for treatment of allograft rejection, graft-versus-host disease, autoimmune inflammatory bowel disease and other disorders in which immunomodulation and tissue repair are required...
  10. ncbi Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells
    K Le Blanc
    Hematology Center, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Leukemia 21:1733-8. 2007
    ..Thus, co-transplantation of MSC resulted in fast engraftment of absolute neutrophil count (ANC) and platelets and 100% donor chimerism, even in three patients regrafted for graft failure/rejection...
  11. ncbi Immunomodulation by mesenchymal stem cells and clinical experience
    K Le Blanc
    Division of Clinical Immunology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    J Intern Med 262:509-25. 2007
    ..Possible clinical applications include therapy-resistant severe acute graft-versus-host disease, tissue repair, treatment of rejection of organ allografts and autoimmune disorders...
  12. ncbi No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients
    Mikael Sundin
    Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Haematologica 92:1208-15. 2007
    ..The objective of this study was to investigate whether antibodies against MSC were present after hematopoietic stem cell transplantation (HSCT) including treatment with matched or mismatched allogeneic MSC...
  13. doi Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy
    Lena von Bahr
    Haematology Centre, Department of Clinical Immunology, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden
    Biol Blood Marrow Transplant 18:557-64. 2012
    ..01). We conclude that treatment with early-passage MSCs improved survival in patients with therapy-resistant GVHD. Death from infection was common in MSC-treated patients, but there was no increase in leukemia relapse...
  14. ncbi The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation
    Mikael Sundin
    Department of Laboratory Medicine, Division of Clinical Immunology F79, Karolinska Institutet, Karolinska University Hospital Huddinge, SE 141 86 Stockholm, Sweden
    Haematologica 91:1059-67. 2006
    ..The objective of this study was to determine risk factors in PTLD following HSCT in order to identify high-risk patients for surveillance, prophylaxis and treatment...
  15. doi Factors with an impact on chimerism development and long-term survival after umbilical cord blood transplantation
    Sofia Berglund
    Centre for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Transplantation 94:1066-74. 2012
    ..Umbilical cord blood transplantation (UCBT) is increasingly used and produces similar results to matched unrelated donor transplantation...
  16. pmc Multipotent mesenchymal stromal cells express FoxP3: a marker for the immunosuppressive capacity?
    Mikael Sundin
    Division of Pediatrics, Department of Clinical Science, Intervention and Technology, Karolinska University Hospital Huddinge, SE 14186 Stockholm, Sweden
    J Immunother 34:336-42. 2011
    ..The increased MSC-mediated suppression of immune responses by immunosuppressive drugs deserves further investigation...
  17. ncbi Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease
    Olle Ringden
    Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Transplantation 81:1390-7. 2006
    ..Mesenchymal stem cells (MSC) have immunomodulatory effects. The aim was to study the effect of MSC infusion on graft-versus-host disease (GVHD)...
  18. ncbi Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes
    Ida Rasmusson
    Division of Clinical Immunology, Karolinska University Hospital, SE 141 86 Stockholm, Sweden
    J Leukoc Biol 82:887-93. 2007
    ..These data may have important implications for the development of therapeutic strategies based on administration of in vitro-expanded MSCs...
  19. ncbi Functional studies of mesenchymal stem cells derived from adult human adipose tissue
    Andrea Dicker
    Department of Medicine, M63, Karolinska Institutet, Karolinska University Hospital, Huddinge, 141 86 Stockholm, Sweden
    Exp Cell Res 308:283-90. 2005
    ..Human adipose-tissue-derived MSCs could therefore constitute an efficient and easily obtainable renewable cellular source for studies of adipocyte biology...
  20. ncbi Immunologic properties of human fetal mesenchymal stem cells
    Cecilia Gotherstrom
    Division of Clinical Immunology, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Am J Obstet Gynecol 190:239-45. 2004
    ..Mesenchymal stem cells (MSCs) can be isolated from adult bone marrow and fetal liver. We investigated the immunologic properties of undifferentiated and differentiated human fetal MSCs...
  21. ncbi Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells
    Katarina Le Blanc
    Division of Clinical Immunology and Centre for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Lancet 363:1439-41. 2004
    ..Clinical response was striking. The patient is now well after 1 year. We postulate that mesenchymal stem cells have a potent immunosuppressive effect in vivo...
  22. ncbi Hemorrhagic cystitis: a retrospective single-center survey
    Zuzana Hassan
    Center for Allogenic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Clin Transplant 21:659-67. 2007
    ..With four risk factors, the risk of HC development was 31%. Risk factors for severe HC of grades 3-5 were aGVHD and bacteremia...
  23. ncbi Allogeneic hematopoietic stem cell transplantation for inherited disorders: experience in a single center
    Olle Ringden
    Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Transplantation 81:718-25. 2006
    ..Allogeneic hematopoietic stem cell transplantation (ASCT) is a possible cure for many inherited disorders...
  24. ncbi Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?
    Olle Ringden
    Centre for Allogeneic Stem Cell Transplantation, Division of Clinical Immunology, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Biol Blood Marrow Transplant 10:128-34. 2004
    ..The 5-year survival was 72%, 48%, and 30% with 0, 1, and 2 risk factors, respectively. We concluded that unrelated hematopoietic stem cell transplantation may be improved if an optimal donor and immunosuppression are chosen...
  25. ncbi Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem cell transplantation
    Regina Jitschin
    Department of Medicine, Karolinska Institutet, Hematology Center, Karolinska University Hospital, Stockholm, Sweden
    Stem Cells 31:1715-25. 2013
    ..Overall, our findings will contribute to the refinement of monitoring tools, for assessing MSC treatment-efficacy and increase our understanding regarding the MSCs' in vivo effects...
  26. doi Targeted intra-arterial transplantation of stem cells to the injured CNS is more effective than intravenous administration: engraftment is dependent on cell type and adhesion molecule expression
    Johan Lundberg
    Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
    Cell Transplant 21:333-43. 2012
    ..In addition, we conclude that careful analysis of cells intended for local, intra-arterial transplantation with respect to integrin expression is important...
  27. ncbi Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms
    Ida Rasmusson
    Division of Clinical Immunology, Karolinska Institutet, Huddinge University Hospital, F79, SE 141 86 Stockholm, Sweden
    Exp Cell Res 305:33-41. 2005
    ..Prostaglandins are important in the inhibition by MSCs when the T cells were activated by PHA, but not alloantigens...
  28. ncbi Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta
    Katarina Le Blanc
    Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital Huddinge, SE 141 86 Stockholm, Sweden
    Transplantation 79:1607-14. 2005
    ..Adult human leukocyte antigen (HLA)-matched MSC have been used in cellular therapies of bone disorders such as osteogenesis imperfecta, with promising results...
  29. ncbi Use of mesenchymal stem cells for the prevention of immune complications of hematopoietic stem cell transplantation
    Katarina Le Blanc
    Division of Clinical Immunology, F79 Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Haematologica 90:438. 2005
  30. ncbi A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation
    Katarina Le Blanc
    Centre for Allogeneic Stem Cell Transplantation and Division of Clinical Immunology, Huddinge University Hospital, Karolinska Institutet, Stockholm, Sweden
    Transplantation 78:1014-20. 2004
    ..Nonmyeloablative (NM) conditioning and reduced-intensity conditioning (RIC) are increasingly used for allogeneic hematopoietic stem-cell transplantation. Such regimens have not been compared...
  31. ncbi Difference in gene expression between human fetal liver and adult bone marrow mesenchymal stem cells
    Cecilia Gotherstrom
    Division of Clinical Immunology, F79, Karolinska University Hospital Huddinge, SE 141 86 Stockholm, Sweden
    Haematologica 90:1017-26. 2005
    ..Fetal and adult MSC have similar morphology but differ in proliferative, differentiating and immunosuppressive properties. Further exploring their differences could help in choosing the right source for cellular therapy...
  32. pmc Persistence of human parvovirus B19 in multipotent mesenchymal stromal cells expressing the erythrocyte P antigen: implications for transplantation
    Mikael Sundin
    Division of Clinical Immunology and Transfusion Medicine, Karolinska Institutet, Stockholm, Sweden
    Biol Blood Marrow Transplant 14:1172-9. 2008
    ..These findings demonstrate for the first time that persistent B19 in MSCs can infect hematopoietic stem cells and underscore the importance of monitoring B19 transmission by MSC products...
  33. ncbi Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood a
    Olle Ringden
    Centre for Allogeneic Stem Cell Transplantation, Division of Clinical Immunology F79, Karolinska Institute, Huddinge University Hospital, SE 141 86 Stockholm, Sweden
    J Clin Oncol 22:416-23. 2004
    ..Granulocyte colony-stimulating factor (G-CSF) is given after bone marrow transplantation (BMT) to shorten the neutropenic phase. Its effects have not been evaluated in a large patient population...
  34. doi Treatment of familial hemophagocytic lymphohistiocytosis with third-party mesenchymal stromal cells
    Dimitrios Mougiakakos
    Division of Clinical Immunology, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Stem Cells Dev 21:3147-51. 2012
    ..If these transient effects of MSCs can be confirmed in future-controlled clinical trials, adoptive MSC therapy could represent a salvage agent in FHL acting as a bridge to definitive treatment with stem cell transplantation...
  35. doi Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study
    Mats Remberger
    Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden
    Biol Blood Marrow Transplant 17:1688-97. 2011
    ..The problem of relapse still has to be remedied. Thus, several different developments together have resulted in significantly lower TRM and improved survival after HSCT over the last few years...
  36. ncbi Allogeneic hematopoietic stem cell transplantation: state of the art and new perspectives
    Olle Ringden
    Karolinska Institutet, Division of Clinical Immunology and Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    APMIS 113:813-30. 2005
    ..They seem to escape the immune system and have immunomodulatory effects in vitro and in vivo. To conclude, ASCT is a potent immunotherapy...
  37. ncbi Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties?
    Guido Moll
    Division of Clinical Immunology and Transfusion Medicine, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden Hematology and Regenerative Medicine Centre at Karolinska University Hospital Huddinge, Stockholm, Sweden
    Stem Cells 32:2430-42. 2014
    ..These changes seem to be paired by differences in therapeutic efficacy in treatment of immune ailments after hematopoietic stem cell transplantation. Stem Cells 2014;32:2430-2442. ..
  38. doi Are therapeutic human mesenchymal stromal cells compatible with human blood?
    Guido Moll
    Division of Clinical Immunology and Transfusion Medicine, Department of Laboratory Medicine, Tumor and Cell Biology MTC, Karolinska Institutet, Stockholm, Sweden
    Stem Cells 30:1565-74. 2012
    ..This deleterious reaction can compromise the survival, engraftment, and function of these therapeutic cells...
  39. pmc Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses
    Guido Moll
    Department of Laboratory Medicine, Clinical Immunology and Transfusion Medicine, Karolinska Institutet and Hematology Center at Karolinska University Hospital Huddinge, Stockholm, Sweden
    PLoS ONE 6:e21703. 2011
    ..Our study demonstrates for the first time a major role of the complement system in governing the immunomodulatory activity of MSCs and elucidates how complement activation mediates the interaction with other immune cells...
  40. ncbi Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells
    Ida Rasmusson
    Department of Clinical Immunology, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Transplantation 76:1208-13. 2003
    ..There are no publications on the effect that MSCs have on cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, effector cells vital for the graft-versus-leukemia effect...
  41. ncbi Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation
    Katarina Le Blanc
    Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Biol Blood Marrow Transplant 11:321-34. 2005
    ..They are also of potential use in the treatment of organ transplant rejection and in autoimmune inflammatory bowel disorders where immunomodulation and tissue repair are needed...
  42. doi Tracheobronchial transplantation with a stem-cell-seeded bioartificial nanocomposite: a proof-of-concept study
    Philipp Jungebluth
    Advanced Center for Translational REGenerative Medicine, Karolinska Institutet, Stockholm, Sweden
    Lancet 378:1997-2004. 2011
    ..We report the clinical transplantation of the tracheobronchial airway with a stem-cell-seeded bioartificial nanocomposite...
  43. doi Fetal and adult multipotent mesenchymal stromal cells are killed by different pathways
    Cecilia Gotherstrom
    Division of Clinical Immunology and Transfusion Medicine, Cancer Center Karolinska, Karolinska Institutet, Stockholm, Sweden
    Cytotherapy 13:269-78. 2011
    ..Recently, there has been considerable interest in MSC because they have features favorable for transplantation, namely their multipotency and non-immunogenic properties...
  44. ncbi Granulocyte and granulocyte-macrophage colony-stimulating factors in allografts: uses, misuses, misconceptions, and future applications
    Olle T H Ringdén
    Center for Allogeneic Stem Cell Transplantation and Division of Clinical Immunology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Exp Hematol 33:505-12. 2005
    ..G-CSF has no effect on relapse. Available findings suggest that there is no indication to use G-CSF as prophylaxis after ASCT...
  45. ncbi Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression
    Garth Cronwright
    Department of Oncology and Pathology, Karolinska Institutet, Sweden
    Cancer Res 65:2207-15. 2005
    ..In addition, E-cadherin expression increases, mimicking a mesenchymal epithelial transition. These results afford SSX a functional role in normal stem cell migration and suggest a potentially similar function in cancer cell metastases...
  46. ncbi Transplantation of embryonic stem cells: possibilities and challenges
    Olle Ringden
    Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Transplantation 76:1011-2. 2003
  47. ncbi A low body mass index is correlated with poor survival after allogeneic stem cell transplantation
    Katarina Le Blanc
    Center for Allogeneic Stem Cell Transplantation, Division of Clinical Immunology, F79, Karolinska Institutet, Huddinge University Hospital, SE 141 86, Stockholm, Sweden
    Haematologica 88:1044-52. 2003
    ..The purpose of this study was to determine whether body mass index (BMI, kg body weight/height (in m2) is related to survival in recipients of allogeneic stem cell transplantation (ASCT)...
  48. pmc Do ABO blood group antigens hamper the therapeutic efficacy of mesenchymal stromal cells?
    Guido Moll
    Division of Clinical Immunology and Transfusion Medicine, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
    PLoS ONE 9:e85040. 2014
    ....
  49. doi The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells
    Dimitrios Mougiakakos
    Karolinska University Hospital Huddinge, Stockholm, Sweden
    Blood 117:4826-35. 2011
    ....
  50. ncbi Functional characterization of human mesenchymal stem cell-derived adipocytes
    Mikael Ryden
    Department of Medicine, Center of Metabolism and Endocrinology, Karolinska Institute, Huddinge University Hospital, 141 86, Stockholm, Sweden
    Biochem Biophys Res Commun 311:391-7. 2003
    ..These systems could be of great value in adipocyte research as a renewable source of adipocytes...
  51. ncbi Defined serum-free media for in vitro expansion of adipose-derived mesenchymal stem cells
    Shahla Hamza Al-Saqi
    Division of Obstetrics and Gynecology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden Electronic address
    Cytotherapy 16:915-26. 2014
    ..The aim of this study was to evaluate a defined serum-free medium for in vitro expansion of MSCs as a prerequisite for their clinical use...
  52. doi Endovascular transplantation of stem cells to the injured rat CNS
    Johan Lundberg
    Department of Clinical Neuroscience, Karolinska Institutet, Department of Neuroradiology, Karolinska University Hospital, 17176 Stockholm, Sweden
    Neuroradiology 51:661-7. 2009
    ..The aim of this investigation was to analyze the effect of intra-arterial administration on cellular engraftment...
  53. pmc Prophylaxis of acute GVHD: manipulate the graft or the environment?
    A John Barrett
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Best Pract Res Clin Haematol 21:165-76. 2008
    ....
  54. ncbi Mesenchymal stem cells combined with cyclosporine inhibits cytotoxic T cells
    Olle Ringden
    Biol Blood Marrow Transplant 12:693-4. 2006
  55. ncbi Concise review: cancer/testis antigens, stem cells, and cancer
    Fabricio F Costa
    Cancer Biology and Epigenomics, Children s Memorial Research Center, 2300 Children s Plaza, Box 220, Chicago, IL 60614 3394, USA
    Stem Cells 25:707-11. 2007
    ..The clinical implications that these trials may have on the normal stem cell pools, as well as the immunologic properties of these cells, is to date poorly studied and should be considered...